Get the Stockscreener App
13.52
4.45%
-0.63
After Hours:
13.25
-0.27
-2.00%
Transcode Therapeutics Inc stock is traded at $13.52, with a volume of 75,198.
It is down -4.45% in the last 24 hours and up +26.36% over the past month.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
See More
Previous Close:
$14.15
Open:
$13.92
24h Volume:
75,198
Relative Volume:
0.51
Market Cap:
$11.27M
Revenue:
-
Net Income/Loss:
$-14.93M
P/E Ratio:
-0.0508
EPS:
-266.137
Net Cash Flow:
$-15.87M
1W Performance:
+14.58%
1M Performance:
+26.36%
6M Performance:
+19.52%
1Y Performance:
-97.91%
1-Day Range:
$13.50
$14.32
1-Week Range:
$11.52
$20.99
52-Week Range:
$6.1478
$720.72
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Name
Transcode Therapeutics Inc
Sector
Industry
Phone
857-301-6857
Address
6 LIBERTY SQUARE, BOSTON
Compare RNAZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
13.52 | 12.98M | 0 | -14.93M | -15.87M | -266.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Transcode Therapeutics Inc Stock (RNAZ) Latest News
Can TransCode Therapeutics Inc. stock weather global recessionWeekly Profit Analysis & Consistent Return Investment Signals - newser.com
Is a relief rally coming for TransCode Therapeutics Inc. holdersJuly 2025 Reactions & Daily Profit Focused Screening - newser.com
Using Bollinger Bands to evaluate TransCode Therapeutics Inc.2025 Breakouts & Breakdowns & Risk Managed Investment Entry Signals - newser.com
Does TransCode Therapeutics Inc. qualify in momentum factor screeningWeekly Trend Summary & AI Driven Price Predictions - newser.com
Heatmap analysis for TransCode Therapeutics Inc. and competitors2025 Market Sentiment & Free Safe Capital Growth Stock Tips - newser.com
Is TransCode Therapeutics Inc. stock poised for growthEarnings Summary Report & Verified High Yield Trade Plans - newser.com
Is TransCode Therapeutics Inc. trending in predictive chart modelsJuly 2025 Intraday Action & Daily Entry Point Alerts - newser.com
Is TransCode Therapeutics Inc. stock oversold or undervaluedMarket Growth Summary & AI Driven Stock Movement Reports - newser.com
Does TransCode Therapeutics Inc. fit your quant trading modelJuly 2025 WrapUp & Accurate Trade Setup Notifications - newser.com
CK Life Merges Polynoma with TransCode in $125M DealNews and Statistics - IndexBox
CK Life Sciences sees low geopolitical risks in a US merger - The Standard (HK)
Multi asset correlation models including TransCode Therapeutics Inc.July 2025 Highlights & Risk Managed Investment Strategies - newser.com
TransCode Therapeutics (NASDAQ:RNAZ) Earns “Sell (E+)” Rating from Weiss Ratings - Defense World
Critical Analysis: Century Therapeutics (NASDAQ:IPSC) and TransCode Therapeutics (NASDAQ:RNAZ) - Defense World
CKLIFE SCIENCES Estimates Completion of TransCode Preferred Stock Conversion in 6 Mths at Earliest - AASTOCKS.com
How hedge fund analytics apply to TransCode Therapeutics Inc. stockJuly 2025 Decliners & Advanced Technical Signal Analysis - newser.com
CK Life unit merges with TransCode as Li Ka-shing firm eyes anticancer drugs - South China Morning Post
TransCode Therapeutics Acquires Polynoma, Secures $25 Million Investment to Advance Oncology Pipeline - citybuzz
TransCode Therapeutics, Inc. (RNAZ) Stock :Soars as $25M Investment and Polynoma Acquisition Ignite Growth Prospects - parameter.io
TransCode Therapeutics To Acquire Polynoma; $25M Financing By a Subsidiary Of CK Life Sciences - citybiz
TransCode Therapeutics to Acquire Polynoma, Receive Investment from CK Life Sciences - MarketScreener
TransCode Makes Bold Bet On Melanoma Vaccine With Polynoma Buyout - Benzinga
TransCode Therapeutics To Acquire Polynoma, Receive $25M Investment To Advance Key Asset - Stocktwits
Transcode announces the acquisition of Polynoma and a $25 mln financing by subsidiary of CK Life Sciences - MarketScreener
TransCode Therapeutics stock soars after Polynoma acquisition By Investing.com - Investing.com Canada
TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company - WV News
Chart based exit strategy for TransCode Therapeutics Inc.2025 Historical Comparison & Expert Verified Stock Movement Alerts - newser.com
Strategies to average down on TransCode Therapeutics Inc.2025 Breakouts & Breakdowns & Risk Managed Investment Entry Signals - newser.com
TransCode Therapeutics Amends Patent License Agreement - TipRanks
TransCode Therapeutics (NASDAQ:RNAZ) Trading Down 1.5% – What’s Next? - Defense World
Will TransCode Therapeutics Inc. stock go up soonMarket Activity Report & Growth Oriented Trade Recommendations - newser.com
Is TransCode Therapeutics Inc. stock bottoming outJuly 2025 Big Picture & Real-Time Volume Analysis Alerts - newser.com
TransCode Therapeutics Passes Key Proposals at Annual Meeting - MSN
Developing predictive dashboards with TransCode Therapeutics Inc. dataMarket Sentiment Review & Safe Capital Allocation Plans - newser.com
Transcode Therapeutics Inc Stock (RNAZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):